Bristol-myers Squibb Compnay

Stephen K Durham

Frederic Moulin

Gregory Opiteck

Leah Ann Garulacan

Stanley Hefta

Oliver P Flint

Jun-Hsiang Lin

Ji Gao

Donna Dambach

Stephen M Storm

The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.

Identification of biomarkers for liver toxicity

The present invention relates to methods of screening drug candidates for toxic effects on human cells. The invention provides methods for determining idiosyncratic toxicity of test compounds.

Methods of screening for toxicity of test compounds

Growing community of inventors

Manlius, NY, United States of America

Stephen K Durham